The Oncosearch | Oncotarget

Coordinate PI3K pathway and Bcl-2 family disruption in AML Editorial

Prithviraj Bose, Mohamed Rahmani, Steven Grant

Published Dec 31, 2012 · Vol. 3, No. 12 · pp. 1499-1500

Keywords: Acute myeloid leukemia, AML, PI3 kinase, Akt, mTOR, Bcl-2, Bcl-xL, Mcl-1, ABT-737, targeted therapies

Advances in Targeting Signal Transduction Pathways. Review

James Andrew McCubrey, Linda S Steelman, William H Chappell, Lin Sun, Nicole M Davis, Stephen L Abrams, Richard A Franklin, Lucio Cocco, Camilla Evangelisti, Francesca Chiarini, Alberto M Martelli, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C Mazzarino, Paolo Fagone, Marco Donia, Ferdinando Nicoletti, Jerry Polesel, Renato Talamini, Jorg Basecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Joanna DuliÅ„ska-Litewka, Piotr Laidler, Antonio B D'Assoro, Lyudmyla Drobot, Kazuo Umezawa, Giuseppe Montalto, Melchiorre Cervello, Zoya N Demidenko

Published Dec 30, 2012 · Vol. 3, No. 12 · pp. 1505-1521

Keywords: Targeted Therapy, Therapy Resistance, Cancer Stem Cells, Raf, Akt, PI3K, mTOR, AMPK, Metformin

Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCIâ€™s provocative questions Research Perspective

Mikhail V. Blagosklonny

Published Dec 30, 2012 · Vol. 3, No. 12 · pp. 1711-1724

Enhancing the Efficacy of Drug-loaded Nanocarriers against Brain Tumors by Targeted Radiation Therapy Research Paper

Brian C. Baumann, Gary D. Kao, Abdullah Mahmud, Takamasa Harada, Joe Swift, Christina Chapman, Xiangsheng Xu, Dennis E. Discher, Jay F. Dorsey

Published Dec 23, 2012 · Vol. 4, No. 1 · pp. 64-79

Keywords: glioblastoma multiforme, nanocarrier, radiation therapy, brain tumors, chemotherapy

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes Research Paper

Filip Janku, Jennifer J. Wheler, Aung Naing, Vanda M. T. Stepanek, Gerald S. Falchook, Siqing Fu, Ignacio Garrido-Laguna, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, David S. Hong, Razelle Kurzrock

Published Nov 30, 2012 · Vol. 3, No. 12 · pp. 1566-1575

Keywords: PIK3CA mutation, phenotypic taxonomy, clinical outcome

Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine Research Paper

Kyung H Yi, Jossette Axtmayer, John P Gustin, Anandita Rajpurohit, Josh Lauring

Published Nov 29, 2012 · Vol. 4, No. 1 · pp. 29-34

Keywords: AKT1, mutation, personalized, cancer, therapy

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) Research Paper

Harald Herrmann, Katharina Blatt, Junwei Shi, Karoline V. Gleixner, Sabine Cerny-Reiterer, Leonhard MÃ¼llauer, Christopher R. Vakoc, Wolfgang R. Sperr, Hans-Peter Horny, James E. Bradner, Johannes Zuber, Peter Valent

Published Nov 27, 2012 · Vol. 3, No. 12 · pp. 1588-1599

Keywords: AML, leukemic stem cells, BRD4, JQ1, targeted therapy

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment Research Paper

SÃlvia CufÃ, Alejandro Vazquez-Martin, Ceistina Oliveras-Ferraros, Bruna Corominas-Faja, Ander Urruticoechea, BegoÃ±a Martin-Castillo, Javier A Menendez

Published Nov 17, 2012 · Vol. 3, No. 12 · pp. 1600-1614

Keywords: Autophagy, ATG genes, HER2, trastuzumab, lapatinib

MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11 Research Paper

Vinayakumar Siragam, Zina Jeyapalan Rutnam, Weining Yang, Ling Fang, Linlin Luo, Xiangling Yan, Minhui Li, Zhaoqun Deng, Jun Qian, Chun Peng, Burton B. Yang

Published Nov 6, 2012 · Vol. 3, No. 11 · pp. 1370-1385

Keywords: microRNA, miR-98, angiogenesis, tumorigenesis, invasion

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance Review

James Andrew McCubrey, Linda S. Steelman, William H. Chappell, Stephen L. Abrams, Richard A. Franklin, Giuseppe Montalto, Melchiorre Cervello, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C. Mazzarino, Paolo Fagone, Ferdinando Nicoletti, JÃ¶rg BÃ¤secke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Francesca Chiarini, Camilla Evangelisti, Lucio Cocco, Alberto M. Martelli

Published Oct 20, 2012 · Vol. 3, No. 10 · pp. 1068-1111

Keywords: Targeted Therapy, Therapy Resistance, Cancer Stem Cells, Raf, Akt, PI3K, mTOR

Recurrent targets of aberrant somatic hypermutation in lymphoma Research Paper

Alireza Hadj Khodabakhshi, Ryan D Morin, Anthony P Fejes, Andrew J Mungall, Karen L Mungall, Madison Bolger-Munro, Nathalie A Johnson, Joseph M Connors, Randy D Gascoyne, Marco A Marra, Inanc Birol, Steven JM Jones

Published Oct 12, 2012 · Vol. 3, No. 11 · pp. 1308-1319

Keywords: Aberrant somatic hypermutation, Genome wide study, Diffuse large B-cell lymphoma, Genomic rearrangements.

Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin Research Paper

Jantine Posthuma De Boer, Pim W. van Egmond, Marco N. Helder, RenÃ©e X. de Menezes, Anne-Marie Cleton-Jansen, Jeroen A.M. BeliÃ«n, Henk M.W. Verheul, Barend J. van Royen, Gert-Jan J.L. Kaspers, Victor W. van Beusechem

Published Sep 28, 2012 · Vol. 3, No. 10 · pp. 1169-1181

Keywords: osteosarcoma, functional genomics, siRNA, chemosensitisation, JIP1

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response. Review

James Andrew McCubrey, Linda Steeman, William Chappell, Stephen Abrams, Giuseppe Montalto, Melchiorre Cervello, Ferdinando Nicoletti, Paolo Fagone, Grazia Malaponte, Maria Mazzarino, Saverio Candido, Massimo Libra, Jorg Basecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Lucio Cocco, Camilla Evangelisti, Francesca Chiarini, Alberto Martelli

Published Sep 20, 2012 · Vol. 3, No. 9 · pp. 954-987

Keywords: targeted therapy, therapy resistance, mutations, Raf, Akt, PI3K, mTOR

Glyceraldehyde-3-Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in Hepatocellular Carcinoma Review

Shanmugasundaram Ganapathy-Kanniappan, Rani Kunjithapatham, Jean-Francois Geschwind

Published Sep 7, 2012 · Vol. 3, No. 9 · pp. 940-953

Keywords: GAPDH, HCC, 3-bromopyruvate

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers Research Paper

Roberto Perez, Andrew V Schally, Irving Vidaurre, Ricardo Rincon, Norman L Block, Ferenc G Rick

Published Aug 30, 2012 · Vol. 3, No. 9 · pp. 988-997

Keywords: neuropeptide analog, tumor gene expression, receptor silencing, targeted therapy, inflammation

Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells Research Paper

Baolin Zhang, Jun-Jie Chen, Jennifer H.-C. Shen, Leslie Rivera Rosado, Yaqin Zhang, Xu Di

Published Aug 19, 2012 · Vol. 3, No. 8 · pp. 833-842

Keywords: death receptors, cellular localization, breast cancer, targeted cancer therapy, drug resistance

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels Research Paper

Daniela Bressanin, Camilla Evangelisti, Francesca Ricci, Giovanna Tabellini, Francesca Chiarini, Pier Luigi Tazzari, Fraia Melchionda, Francesca Buontempo, Pasqualepaolo Pagliaro, Andrea Pession, James A McCubrey, Alberto M. Martelli

Published Aug 9, 2012 · Vol. 3, No. 8 · pp. 811-823

Keywords: acute leukemia, targeted therapy, signal transduction modulators, PI3K/PDK1, vertical inhibition

Mutant IDH1 is required for IDH1 mutated tumor cell growth Brief Reports

Genglin Jin, Christopher J. Pirozzi, Lee H. Chen, Christopher G. Duncan, Giselle Y. Lopez, Jie Feng, Ivan Spasojevic, Darell D. Bigner, Yiping He, Hai Yan

Published Aug 9, 2012 · Vol. 3, No. 8 · pp. 774-782

Keywords: IDH1, cell survival

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108) Research Paper

Karoly Szepeshazi, Andrew V Schally, Gunhild Keller, Norman L Block, Daniel Benten, Gabor Halmos, Luca Szalontay, Irving Vidaurre, Miklos Jaszberenyi, Ferenc G Rick

Published Jul 22, 2012 · Vol. 3, No. 7 · pp. 686-699

Keywords: urinary bladder, urothelial cancer, targeted therapy, LH-RH receptor, cytotoxic, doxorubicin

Accelerating cancer evolution: a dark side of SIRT1 in genome maintenance Editorial Comments

WenYong Chen

Published May 9, 2012 · Vol. 3, No. 4 · pp. 363-364

Keywords: SIRT1, CML, cancer evolution, mutation acquisition, targeted therapy

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Coordinate PI3K pathway and Bcl-2 family disruption in AML Editorial

Advances in Targeting Signal Transduction Pathways. Review

Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCIâ€™s provocative questions Research Perspective

Enhancing the Efficacy of Drug-loaded Nanocarriers against Brain Tumors by Targeted Radiation Therapy Research Paper

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes Research Paper

Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine Research Paper

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) Research Paper

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment Research Paper

MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11 Research Paper

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance Review

Recurrent targets of aberrant somatic hypermutation in lymphoma Research Paper

Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin Research Paper

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response. Review

Glyceraldehyde-3-Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in Hepatocellular Carcinoma Review

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers Research Paper

Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells Research Paper

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels Research Paper

Mutant IDH1 is required for IDH1 mutated tumor cell growth Brief Reports

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108) Research Paper

Accelerating cancer evolution: a dark side of SIRT1 in genome maintenance Editorial Comments

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Coordinate PI3K pathway and Bcl-2 family disruption in AML Editorial

Advances in Targeting Signal Transduction Pathways. Review

Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCIâ€™s provocative questions Research Perspective

Enhancing the Efficacy of Drug-loaded Nanocarriers against Brain Tumors by Targeted Radiation Therapy Research Paper

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes Research Paper

Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine Research Paper

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) Research Paper

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment Research Paper

MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11 Research Paper

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance Review

Recurrent targets of aberrant somatic hypermutation in lymphoma Research Paper

Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin Research Paper

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response. Review

Glyceraldehyde-3-Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in Hepatocellular Carcinoma Review

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers Research Paper

Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells Research Paper

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels Research Paper

Mutant IDH1 is required for IDH1 mutated tumor cell growth Brief Reports

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108) Research Paper

Accelerating cancer evolution: a dark side of SIRT1 in genome maintenance Editorial Comments